LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN

• DOI: 10.4149/neo_2021_210205n184
• Publication Date: 2021-05-26T07:11:02Z
• Authors: Li-Hui Yang; Peng Du; Wei Liu; Li-Kun An; Jian Li; Wen-Yi Zhu; Shuo Yuan; Lei Wang; Lei Zang
• Keywords: Chromatin immunoprecipitation

Multiple myeloma (MM) is a plasma cell malignancy of bone marrow. In the present study, we aimed to study function and potential mechanism antisense non-coding RNA in INK4 Locus (ANRIL) MM. The expression levels ANRIL MM patients healthy donors were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). effects mechanisms viability assay, BrdU incorporation tumor xenograft model, flow cytometry, western blot, immunoprecipitation (RIP), transcriptome sequencing, chromatin (ChIP). We found that was upregulated lines, associated with advanced international staging system (ISS) stage poor overall survival. Enforced promoted proliferation growth cells, while knockdown exhibited opposite effects. Moreover, overexpression increased half-maximal inhibitory concentration (IC50) bortezomib reduced bortezomib-induced apoptosis cells. accumulate nuclei interact EZH2 RIP assay. Transcriptome sequencing identified PTEN as target ChIP occupancy H3K27me3 binding promoter region PTEN. Furthermore, knockout or restoration abrogated caused Our results indicated exerted oncogenic functions conferred chemoresistance cells EZH2-mediated epigenetically silencing